The worldwide market for surgical heart valve products is expected to stay relatively flat, reaching $2bn in sales by 2023. The heart valve repair and replacement segments are expected to see small losses while the much smaller PBV systems market will grow at a CAGR of 12.7% by 2023, benefiting from a trend toward minimally invasive procedures.

Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.

The classification orders touch on surgical, weight loss and cardiac devices and diagnostics.

Improving the patient’s QoL and preventing disease progression, and with it the threat of critical limb ischemia and amputation, dominate peripheral artery disease management, but emerging technologies and the aging population are set to boost a percutaneous transluminal angioplasty market that is already worth $730 million in the US alone.